DEFA14A: NovaBay CEO Lazar Resigns Amid 90% Stock Transfer

NovaBay Pharmaceuticals' CEO David Lazar resigned, effective upon the transfer of his preferred stock and rights to R01 Fund LP and Framework Ventures IV L.P., who are expected to collectively own 90% of the company's common stock.

Summary

• David Lazar resigned as Chief Executive Officer and a director of NovaBay Pharmaceuticals, Inc., with his resignation effective upon the release of Escrow Funds.
• Mr. Lazar entered into a Securities Purchase Agreement on October 9, 2025, with R01 Fund LP and Framework Ventures IV L.P. (the Purchasers).
• Under this agreement, Mr. Lazar is assigning his right, title, and interest in 441,325 shares of Series D Non-Voting Convertible Preferred Stock and the rights and obligations to purchase 268,750 shares of Series E Non-Voting Convertible Preferred Stock to the Purchasers.
• This transaction is contingent on the approval by NovaBay's stockholders of proposals 5 and 9 at the 2025 Annual Meeting of stockholders, scheduled for October 16, 2025.
• Upon approval of the Investment Transaction and Related Transactions and completion of the First Closing and Final Closing, the Purchasers are expected to collectively beneficially own approximately 90% of NovaBay's outstanding common stock.
• NovaBay Pharmaceuticals agreed to perform its covenants and obligations pursuant to the August 19, 2025, Securities Purchase Agreement for the benefit of the new Purchasers.

Sentiment

Score: 6

Explanation: While a CEO departure can be seen as negative, the structured transfer of a large block of shares to new institutional investors could bring stability and a clear strategic direction, assuming shareholder approval. The 90% ownership concentration is a double-edged sword, offering control but potentially reducing public float and minority shareholder influence.

Positives

• The structured transfer of a significant block of shares to new institutional investors could lead to more stable governance and a clearer strategic direction.
• NovaBay Pharmaceuticals is upholding its prior agreements, ensuring continuity and fulfilling obligations for the benefit of the new purchasers.

Negatives

• The departure of the Chief Executive Officer and a director, David Lazar, could introduce a period of leadership transition and potential uncertainty.
• The transaction is contingent on stockholder approval, which introduces a degree of uncertainty until the October 16, 2025, Annual Meeting.
• A single group of purchasers gaining approximately 90% beneficial ownership could significantly reduce the public float and influence of minority shareholders.

Risks

• Risk of stockholder disapproval of proposals 5 and 9 at the 2025 Annual Meeting, which would prevent the stock transfer and the CEO's resignation from becoming effective.
• Potential for disruption or strategic shifts during the transition period following the CEO's departure and the change in majority ownership.
• Highly concentrated ownership (approximately 90%) by the Purchasers could lead to reduced liquidity for common stock and diminished influence for other shareholders.

Future Outlook

Upon stockholder approval of proposals 5 and 9 and completion of the First Closing and Final Closing, R01 Fund LP and Framework Ventures IV L.P. are expected to collectively beneficially own approximately 90% of the outstanding common stock of NovaBay Pharmaceuticals, Inc.

Management Comments

• Tommy Law, Chief Financial Officer, signed the report on behalf of NovaBay Pharmaceuticals, Inc.

Industry Context

This filing details a significant internal corporate governance and ownership restructuring for NovaBay Pharmaceuticals, Inc., rather than reflecting broader industry trends. The substantial change in beneficial ownership could reposition the company within its competitive landscape, depending on the strategic direction of the new majority owners.

Management Changes

Corporate Governance

Related Party Transactions

• David Lazar, the resigning CEO and director, is the seller in the Securities Purchase Agreement, transferring his preferred stock and rights to the Purchasers.

Stakeholder Impact

• Shareholders: Significant change in ownership structure, potentially impacting liquidity and control for minority shareholders. Voting on key proposals (5 and 9) is critical.
• Management/Employees: Departure of the CEO signals a leadership transition, which may lead to further organizational changes.
• Creditors/Suppliers: No direct impact mentioned, but a stable, well-capitalized ownership group could be viewed positively.

Next Steps

• Stockholders are to vote on proposals 5 and 9 at the 2025 Annual Meeting on October 16, 2025.
• Release of Escrow Funds to David Lazar upon the effectiveness of his resignation.
• Completion of the First Closing and Final Closing of the stock transfer upon stockholder approval.

Key Dates

Recommendation

The filing details a significant corporate restructuring involving the resignation of the CEO and a transfer of a substantial 90% beneficial ownership to new institutional investors. While the departure of a CEO can introduce uncertainty, the consolidation of ownership by R01 Fund LP and Framework Ventures IV L.P. could lead to a more focused strategic direction and potentially greater stability. However, the high concentration of ownership may reduce public float and minority shareholder influence. Investors should hold to assess the new management's strategy and the impact of the concentrated ownership structure post-approval and closing.

Keywords

NovaBay Pharmaceuticals, NBY, CEO Resignation, Stock Transfer, Preferred Stock, Securities Purchase Agreement, Corporate Governance, Shareholder Meeting, R01 Fund LP, Framework Ventures IV L.P.